Annual Working Capital
$946.24 M
+$312.31 M+49.27%
December 31, 2024
Summary
- As of February 22, 2025, HALO annual working capital is $946.24 million, with the most recent change of +$312.31 million (+49.27%) on December 31, 2024.
- During the last 3 years, HALO annual working capital has risen by +$137.10 million (+16.94%).
- HALO annual working capital is now at all-time high.
Performance
HALO Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Working Capital
N/A
December 31, 2024
Summary
- HALO quarterly working capital is not available.
Performance
HALO Quarterly Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Working Capital Formula
Working Capital = Current Assets − Current Liabilities
HALO Working Capital Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +49.3% | - |
3 y3 years | +16.9% | - |
5 y5 years | +106.7% | - |
HALO Working Capital Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +55.6% | ||
5 y | 5-year | at high | +609.4% | ||
alltime | all time | at high | >+9999.0% |
Halozyme Therapeutics Working Capital History
Date | Annual | Quarterly |
---|---|---|
Dec 2024 | $946.24 M(+49.3%) | - |
Sep 2024 | - | $1.02 B(+19.2%) |
Jun 2024 | - | $854.44 M(+15.2%) |
Mar 2024 | - | $741.95 M(+17.0%) |
Dec 2023 | $633.93 M(+4.2%) | $633.93 M(-17.0%) |
Sep 2023 | - | $763.82 M(+17.6%) |
Jun 2023 | - | $649.35 M(+24.1%) |
Mar 2023 | - | $523.10 M(-14.0%) |
Dec 2022 | $608.22 M(-24.8%) | $608.22 M(+11.8%) |
Sep 2022 | - | $543.82 M(+58.8%) |
Jun 2022 | - | $342.43 M(-61.0%) |
Mar 2022 | - | $877.00 M(+8.4%) |
Dec 2021 | $809.14 M(+506.6%) | $809.14 M(-10.5%) |
Sep 2021 | - | $904.15 M(+2.1%) |
Jun 2021 | - | $885.50 M(+6.1%) |
Mar 2021 | - | $834.30 M(+525.5%) |
Dec 2020 | $133.38 M(-70.9%) | $133.38 M(-71.7%) |
Sep 2020 | - | $471.92 M(-0.5%) |
Jun 2020 | - | $474.29 M(+11.3%) |
Mar 2020 | - | $425.97 M(-7.0%) |
Dec 2019 | $457.80 M(+64.4%) | $457.80 M(+95.6%) |
Sep 2019 | - | $234.00 M(-8.7%) |
Jun 2019 | - | $256.29 M(-5.2%) |
Mar 2019 | - | $270.37 M(-2.9%) |
Dec 2018 | $278.49 M(-26.5%) | $278.49 M(-4.2%) |
Sep 2018 | - | $290.81 M(-11.8%) |
Jun 2018 | - | $329.60 M(-9.8%) |
Mar 2018 | - | $365.25 M(-3.6%) |
Dec 2017 | $379.04 M(+87.7%) | $379.04 M(+50.8%) |
Sep 2017 | - | $251.30 M(-2.7%) |
Jun 2017 | - | $258.22 M(+60.7%) |
Mar 2017 | - | $160.65 M(-20.5%) |
Dec 2016 | $201.95 M(+84.7%) | $201.95 M(-8.2%) |
Sep 2016 | - | $219.94 M(-10.4%) |
Jun 2016 | - | $245.46 M(+5.4%) |
Mar 2016 | - | $232.81 M(+113.0%) |
Dec 2015 | $109.31 M(-20.2%) | $109.31 M(+1.0%) |
Sep 2015 | - | $108.24 M(-18.9%) |
Jun 2015 | - | $133.40 M(+4.9%) |
Mar 2015 | - | $127.12 M(-7.2%) |
Dec 2014 | $136.99 M(+94.9%) | $136.99 M(+10.5%) |
Sep 2014 | - | $124.01 M(-13.8%) |
Jun 2014 | - | $143.90 M(-6.9%) |
Mar 2014 | - | $154.55 M(+119.9%) |
Dec 2013 | $70.29 M | $70.29 M(+11.2%) |
Date | Annual | Quarterly |
---|---|---|
Sep 2013 | - | $63.19 M(-6.5%) |
Jun 2013 | - | $67.59 M(-26.0%) |
Mar 2013 | - | $91.36 M(-18.2%) |
Dec 2012 | $111.68 M(+139.2%) | $111.68 M(+32.0%) |
Sep 2012 | - | $84.58 M(-18.3%) |
Jun 2012 | - | $103.58 M(-10.6%) |
Mar 2012 | - | $115.89 M(+148.2%) |
Dec 2011 | $46.69 M(-37.0%) | $46.69 M(-26.1%) |
Sep 2011 | - | $63.18 M(+11.9%) |
Jun 2011 | - | $56.47 M(-15.2%) |
Mar 2011 | - | $66.59 M(-10.2%) |
Dec 2010 | $74.16 M(+23.5%) | $74.16 M(-14.4%) |
Sep 2010 | - | $86.65 M(+126.5%) |
Jun 2010 | - | $38.26 M(-21.8%) |
Mar 2010 | - | $48.92 M(-18.5%) |
Dec 2009 | $60.04 M(+0.4%) | $60.04 M(-11.2%) |
Sep 2009 | - | $67.59 M(-13.9%) |
Jun 2009 | - | $78.48 M(+48.5%) |
Mar 2009 | - | $52.85 M(-11.6%) |
Dec 2008 | $59.79 M(-35.2%) | $59.79 M(-11.0%) |
Sep 2008 | - | $67.17 M(-12.4%) |
Jun 2008 | - | $76.71 M(-11.8%) |
Mar 2008 | - | $87.02 M(-5.7%) |
Dec 2007 | $92.31 M(+123.3%) | $92.31 M(-7.5%) |
Sep 2007 | - | $99.81 M(+3.0%) |
Jun 2007 | - | $96.94 M(+42.3%) |
Mar 2007 | - | $68.14 M(+64.8%) |
Dec 2006 | $41.34 M(+132.2%) | $41.34 M(+183.7%) |
Sep 2006 | - | $14.57 M(+3.9%) |
Jun 2006 | - | $14.03 M(-11.7%) |
Mar 2006 | - | $15.89 M(-10.8%) |
Dec 2005 | $17.80 M(+22.2%) | $17.80 M(+247.3%) |
Sep 2005 | - | $5.13 M(-42.0%) |
Jun 2005 | - | $8.83 M(-24.0%) |
Mar 2005 | - | $11.61 M(-20.3%) |
Dec 2004 | $14.57 M(>+9900.0%) | $14.57 M(+799.5%) |
Sep 2004 | - | $1.62 M(-65.8%) |
Jun 2004 | - | $4.73 M(-30.3%) |
Mar 2004 | - | $6.80 M(>+9900.0%) |
Sep 2003 | - | $60.90 K(-10.2%) |
Jun 2003 | - | $67.80 K(-12.5%) |
Mar 2003 | - | $77.50 K(-27.7%) |
Sep 2002 | - | $107.20 K(-10.1%) |
Jun 2002 | - | $119.20 K(+263.4%) |
Mar 2002 | - | $32.80 K |
Dec 2001 | $22.80 K | - |
FAQ
- What is Halozyme Therapeutics annual working capital?
- What is the all time high annual working capital for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual working capital year-on-year change?
- What is the all time high quarterly working capital for Halozyme Therapeutics?
What is Halozyme Therapeutics annual working capital?
The current annual working capital of HALO is $946.24 M
What is the all time high annual working capital for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual working capital is $946.24 M
What is Halozyme Therapeutics annual working capital year-on-year change?
Over the past year, HALO annual working capital has changed by +$312.31 M (+49.27%)
What is the all time high quarterly working capital for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly working capital is $1.02 B